<DOC>
	<DOCNO>NCT02657161</DOCNO>
	<brief_summary>Phase I clinical study investigational PIKA ( Polyinosinic-Polycytidylic Acid Based Adjuvant ) rabies vaccine comprise Inactivated Purified Rabies Virus ( IPRV ) PIKA adjuvant . The primary objective study assess clinical safety vaccine composition healthy adult volunteer . The secondary objective evaluate vaccine 's efficacy base accelerated vaccine regimen .</brief_summary>
	<brief_title>Safety Efficacy PIKA Rabies Vaccine Containing PIKA Adjuvant</brief_title>
	<detailed_description>A single-center , open label , randomized phase I study healthy naïve adult subject . There three study group ; subject randomly assign group A ( 12 ) , B ( 12 ) C ( 12 ) . Group A , control arm study , receive commercially available rabies vaccine , RABIPUR® Group B receive dos investigational PIKA rabies vaccine . Group C receive accelerated vaccine regimen investigational PIKA rabies vaccine . Group A B follow vaccine regimen ( 1-1-1-1 ) , one injection day 0 , 3 , 7 14 administer respectively . Group C receive accelerated regimen ( 2-2-1 ) , two injection day 0 3 administer different arm ; one injection administer day 7 . Each vaccine dose comprise 1.0 ml PIKA rabies vaccine Group B Group C 1.0 ml RABIPUR® Group A reconstitution . The route administration intramuscular injection , give deltoid region arm .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Informed consent form sign date Able attend schedule visit comply trial procedure . Never receive rabies vaccine . Refrain blood donation course study . Able attend schedule visit comply trial procedure . For woman pregnant breastfeed Previous vaccination rabies ( pre postexposure regimen ) either trial vaccine another vaccine History allergy medicine ( S ) , convulsion , epilepsy , mental illness brain disease clear serious systemic reaction Known bleeding disorder suspect impairment immunologic function , receipt immunosuppressive therapy immunoglobulin since birth Participation interventional clinical trial Donation blood within last 2 month donate plasma within last 14 day Patient clinical sign encephalitis Recipient vaccine 4 week precede first trial vaccination , except influenza vaccination Concomitant use high probability expect concomitant use plan study medication immune suppressant , steroid , nonstudy vaccine similar substance Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins and/or blood product within 3 month prior first dose study vaccine plan administration study period . History allergic disease reaction likely exacerbate component study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Uncontrolled acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Chronic administration immunosuppressant immunemodifying drug within 3 month prior first vaccine dose . Clinical Manifestation Metabolic , blood system , lung , heart , gastrointestinal tract , nervous system , kidney , urinary system , endocrine , liver disease malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>